LT2002031A - Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai - Google Patents

Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai

Info

Publication number
LT2002031A
LT2002031A LT2002031A LT2002031A LT2002031A LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A
Authority
LT
Lithuania
Prior art keywords
prevention
treatment
mesoprogestins
disorders
progesterone receptor
Prior art date
Application number
LT2002031A
Other languages
English (en)
Other versions
LT5034B (lt
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of LT2002031A publication Critical patent/LT2002031A/lt
Publication of LT5034B publication Critical patent/LT5034B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Šiame išradime yra aprašomi mezoprogestinai - nauja progesterono receptoriaus moduliatorių (PRM) klasė, skirta panaudoti gerybinių nuo hormonų priklausomų ginekologinių sutrikimų gydymui ir prevencijai: a) ginekologinių sutrikimų, tokių kaip endometriozė, gimdos fibromos, pooperaciniai pilvaplėvės suaugimai, kraujavimo funkcijos sutrikimai (metroragija, menoragija) ir dismenorėja, gydymui; b) ginekologinių sutrikimų, tokių kaip pooperaciniai pilvaplėvės suaugimai, gimdos kraujavimo funkcijos sutrikimai (metroragija, menoragija) ir dismenorėja, prevencijai, ir c) moteriškos lyties gyvūnų, ypatingai moterų, kurioms yra reikalingas vieno ar daugiau tokių sutrikimų gydymas, gydymui arba prevencijai, naudojant efektyvų mezoprogestino kiekį. Mezoprogestinais yra vadinami junginiai, kurie turi ir agonistinį, ir antagonistinį poveikį į progesterono receptorių (PR) in vivo. Jie stabilizuoja PR funkciją tarpiniame lygmenyje tarp agonistinio ir antagonistinio. Atitinkamų funkcinių būsenų negalima pasiekti naudojant progestinus arba antiprogestinus. Mezoprogestinų dienos dozė yra 0,5-100 mg, geriau 5,0-50 mg, o geriausia 10-25 mg. Pagal šį išradimą tinkamiausiais mezoprogestinais yra J867, J912, J956 ir J1042.ą
LT2002031A 1999-08-31 2002-03-21 Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai LT5034B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
LT2002031A true LT2002031A (lt) 2003-02-25
LT5034B LT5034B (lt) 2003-07-25

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002031A LT5034B (lt) 1999-08-31 2002-03-21 Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai

Country Status (34)

Country Link
EP (1) EP1229906B1 (lt)
JP (1) JP2003535029A (lt)
KR (3) KR20080066095A (lt)
AR (1) AR025457A1 (lt)
AT (1) ATE375160T1 (lt)
AU (1) AU781840B2 (lt)
BG (1) BG65817B1 (lt)
BR (1) BR0014161A (lt)
CA (1) CA2382580C (lt)
CO (1) CO5200772A1 (lt)
CZ (1) CZ2002704A3 (lt)
DE (1) DE60036723T2 (lt)
DK (1) DK1229906T3 (lt)
EA (1) EA007854B1 (lt)
EE (1) EE05172B1 (lt)
ES (1) ES2295050T3 (lt)
HR (1) HRP20020267A2 (lt)
HU (1) HUP0202429A3 (lt)
IL (1) IL148416A0 (lt)
LT (1) LT5034B (lt)
LV (1) LV12941B (lt)
ME (1) MEP13808A (lt)
MX (1) MXPA02002191A (lt)
NO (1) NO20020999L (lt)
NZ (1) NZ517471A (lt)
PE (1) PE20010578A1 (lt)
PL (1) PL198790B1 (lt)
PT (1) PT1229906E (lt)
RO (1) RO122179B1 (lt)
RS (1) RS50283B (lt)
SI (1) SI20852B (lt)
SK (1) SK287192B6 (lt)
UA (1) UA78184C2 (lt)
WO (1) WO2001015679A2 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
JP4709328B2 (ja) * 2009-06-17 2011-06-22 国立大学法人 熊本大学 月経困難症の予防及び／又は治療薬
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
UA37259C2 (uk) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Also Published As

Publication number Publication date
ATE375160T1 (de) 2007-10-15
PL353930A1 (en) 2003-12-15
CA2382580C (en) 2009-05-19
PT1229906E (pt) 2008-01-18
RS50283B (sr) 2009-09-08
KR20070058023A (ko) 2007-06-07
HUP0202429A3 (en) 2004-04-28
LT5034B (lt) 2003-07-25
WO2001015679A3 (en) 2001-11-22
EE05172B1 (et) 2009-06-15
UA78184C2 (en) 2007-03-15
MEP13808A (en) 2010-06-10
JP2003535029A (ja) 2003-11-25
SI20852A (sl) 2002-10-31
DE60036723D1 (de) 2007-11-22
EE200200104A (et) 2003-04-15
AU781840B2 (en) 2005-06-16
KR20020027616A (ko) 2002-04-13
ES2295050T3 (es) 2008-04-16
KR100864547B1 (ko) 2008-10-20
NZ517471A (en) 2004-02-27
DK1229906T3 (da) 2008-02-11
EA200200282A1 (ru) 2002-10-31
WO2001015679A2 (en) 2001-03-08
CZ2002704A3 (cs) 2003-02-12
AU6946600A (en) 2001-03-26
PE20010578A1 (es) 2001-06-04
CA2382580A1 (en) 2001-03-08
CO5200772A1 (es) 2002-09-27
NO20020999L (no) 2002-03-14
YU14002A (sh) 2006-01-16
DE60036723T2 (de) 2008-07-17
BG65817B1 (bg) 2010-01-29
SK287192B6 (sk) 2010-02-08
HUP0202429A2 (en) 2002-10-28
BR0014161A (pt) 2002-05-21
EA007854B1 (ru) 2007-02-27
KR100755109B1 (ko) 2007-09-04
EP1229906A2 (en) 2002-08-14
AR025457A1 (es) 2002-11-27
NO20020999D0 (no) 2002-02-28
BG106442A (bg) 2002-09-30
MXPA02002191A (es) 2002-09-30
EP1229906B1 (en) 2007-10-10
RO122179B1 (ro) 2009-02-27
PL198790B1 (pl) 2008-07-31
SK2992002A3 (en) 2002-07-02
SI20852B (sl) 2009-06-30
IL148416A0 (en) 2002-09-12
HRP20020267A2 (en) 2004-04-30
LV12941B (en) 2003-06-20
KR20080066095A (ko) 2008-07-15

Similar Documents

Publication Publication Date Title
NO964155L (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
LT2002031A (lt) Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai
DK0792152T3 (da) Fremgangsmåder til svangerskabsforebyggelse
CA2182183A1 (en) Treatment of ovarian estrogen dependent conditions
WO2004000801A3 (en) Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
WO2004000225A3 (en) Use of thio-oxindole derivatives in treatment of hormone-related conditions
HK1045816A1 (zh) 角质细胞生长因子-2制剂
WO2007016385A3 (en) Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
BG105761A (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2002072106A3 (en) Combined method for treating hormono-dependent disorders with exemestane
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
SI1355906T1 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
BG102682A (bg) Система за освобождаване на контрацептиви с бактерицидно и/или антивирусно действие
WO2001026603A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
CL2003001545A1 (es) Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei
EA200200285A1 (ru) Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт)
WO2000061230A3 (en) Estrogen receptors-beta antagonism and bone diseases
Tsuga Full automatic vegetable transplanter
EP1400810A3 (en) Estrogen receptors and bone disease
HUP0200244A3 (en) Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: SCHERING AKTIENGESELLSCHAFT, DE

Effective date: 20050104

MM9A Lapsed patents

Effective date: 20100831